{
    "clinical_study": {
        "@rank": "52096", 
        "arm_group": {
            "arm_group_label": "FGTW", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate clinical pharmacology, efficacy and safety of  FGTW in\n      pediatric patients with congenital fibrinogen deficiency."
        }, 
        "brief_title": "Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency", 
        "condition": [
            "Hypofibrinogenemia, Congenital", 
            "Afibrinogenemia, Congenital"
        ], 
        "condition_browse": {
            "mesh_term": "Afibrinogenemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed and dated informed consent form by parents or a legal representative\n\n          -  Age less or equal to 12 years old\n\n          -  Patients with inherited afibrinogenemia or severe inherited hypofibrinogenemia\n\n          -  Negative results on HCG-based pregnancy test for females of childbearing potential\n             (presence of menstruation)\n\n        Exclusion Criteria:\n\n          -  Dysfibrinogenemia\n\n          -  Acquired fibrinogen deficiency\n\n          -  Suspected present or past anticoagulation inhibitor\n\n          -  Personal history of venous or arterial thrombosis or thromboembolic event\n\n          -  Co-morbidity with other/unrelated coagulopathies\n\n          -  Administration of any fibrinogen concentrate or fibrinogen containing blood product\n             during the last 15 days\n\n          -  Permanent treatment with antithrombotic or anti-platelet agents such as heparins,\n             anti-IIa or anti-Xa agents, aspirin, clopidogrel and NSAIDs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094430", 
            "org_study_id": "FGTW-1004"
        }, 
        "intervention": {
            "arm_group_label": "FGTW", 
            "intervention_name": "biological: human fibrinogen concentrate", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75015"
                    }, 
                    "name": "Hopital Necker enfants malades"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon"
                    }, 
                    "name": "H\u00f4pital H\u00f4tel Dieu"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rabat", 
                        "country": "Morocco"
                    }, 
                    "name": "H\u00f4pital d'enfants - CHU Avicenne"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey"
                    }, 
                    "name": "Faculty Ihsan Dogramaci Children's Hospital"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Lebanon", 
                "Morocco", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Pharmacology, Efficacy and Safety Study of FGTW in Paediatric Patients With Severe Congenital Fibrinogen Deficiency", 
        "overall_contact": {
            "last_name": "Eric NEUHART, MD", 
            "phone": "33 (0) 1 69 82 70 87"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes", 
                "Lebanon: Institutional Review Board", 
                "Morocco: Ministry of Public Health", 
                "Morocco: Ethics Committee", 
                "Turkey: Ethics Committee", 
                "Turkey: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Investigator's overall assessment of efficacy of FGTW on hemostasis  using a 4-point scale at the end of each bleeding or surgical episode.", 
                "safety_issue": "No", 
                "time_frame": "6 hours or up to 5 days"
            }, 
            {
                "measure": "Terminal half life for Fibrinogen antigen and activity", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of their participation in the study, an expected average of 1 year"
        }, 
        "source": "Laboratoire fran\u00e7ais de Fractionnement et de Biotechnologies", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratoire fran\u00e7ais de Fractionnement et de Biotechnologies", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}